Takeaway
-
Routine cardiac testing before, during, or after treatment with pegylated liposomal doxorubicin (PLD) may not be necessary in patients with gynecologic cancer.
Why this matters
-
The manufacturer recommends evaluations via endomyocardial biopsy, echocardiography, or multigated acquisition scan (MUGA) before and during treatment. Findings suggest testing could be reserved for high-risk patients.
Study design
- Researchers analyzed the health records of 235 patients (mean age, 62±11 years, 37% black) receiving PLD for gynecologic cancer.
- A Wilcoxon signed-rank sum test and logistic regression were used to evaluate the association between cumulative PLD exposure with cardiotoxicity.
- Funding: National Institutes of Health.
Key results
- Data for 56 patients with both pre- and posttreatment cardiac testing showed no significant difference in median ejection fraction (P=.17).
- 3 patients experienced PLD-associated cardiac toxicity, but only 1 patient had severe symptoms requiring treatment discontinuation.
Limitations
- Retrospective, observational data.
Only healthcare professionals with a Univadis account have access to this article.
You have reached your limit of complementary articles
Free Sign Up Available exclusively to healthcare professionals